Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Not yet recruiting 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Other hematologic neoplasm 2Myeloid 2Gynecologic 2Gastrointestinal 2Tumor-Agnostic 1

Conditions

Carcinoma, Hepatocellular 2Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 150Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 62Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Tyrosine Kinase Inhibitors × Gastrointestinal × Clear all
NCT06232759 2024-06-10

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

Guangxi Medical University

Phase 2 Completed
56 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Bayer

Phase 2 Completed
6 enrolled 11 charts
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡